Malaria Information and Prophylaxis, by Country [S]

Print
Related Pages

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Saint Helena (U.K.) None Not Applicable Not Applicable Not Applicable
Saint Kitts (Saint Christopher) and Nevis (U.K.) None Not Applicable Not Applicable Not Applicable
Saint Lucia None Not Applicable Not Applicable Not Applicable
Saint Pierre and Miquelon (France) None Not Applicable Not Applicable Not Applicable
Saint Vincent and the Grenadines None Not Applicable Not Applicable Not Applicable
Samoa (formerly Western Samoa) None Not Applicable Not Applicable Not Applicable
San Marino None Not Applicable Not Applicable Not Applicable
São Tomé and Príncipe All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Saudi Arabia Regions of Asir and Jazan near the border with Yemen only. None in the cities of Jeddah, Mecca, Medina, Riyadh, and Ta’if. Chloroquine Primarily P. falciparum;

P. vivax rare

 Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5 1) City(ies) of travel
2) Region(s) of travel
To determine if a city is within a certain region
Map of regions of Saudi Arabia
Senegal All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Serbia None Not Applicable Not Applicable Not Applicable
Seychelles None Not Applicable Not Applicable Not Applicable
Sierra Leone All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Singapore None Not Applicable Not Applicable Not Applicable
Slovakia None Not Applicable Not Applicable Not Applicable
Slovenia None Not Applicable Not Applicable Not Applicable
Solomon Islands All Chloroquine P. vivax 70%;P. falciparum 30%;
P. ovale <1%		 Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Somalia All Chloroquine P. falciparum 90%,

P. vivax 5%-10%,

P. malariae, and P. ovale rare

 Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
South Africa Present along the border with Zimbabwe and Mozambique. Specifically, in Mopani and Vhembe Districts of Limpopo Province; Ehlanzeni District of Mpumalanga Province; Umknanyakude District of Kwazulu-Natal Province. Present in Kruger National Park. Few cases in Waterburg, Capricorn, and Greater Sekhukhune Districts of Limpopo Province; Zululand and King Cetshwayo Districts of Kwazulu-Natal Province. Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Mopani and Vhembe Districts of Limpopo Province; Ehlanzeni District of Mpumalanga Province; Umknanyakude District of Kwazulu-Natal Province; and in Kruger National Park:
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5

Other areas with malaria: None (mosquito avoidance only).6

 Province(s) of travel

Provinces of South Africa to determine if a city is within a certain province
South Georgia and the South Sandwich Islands None Not Applicable Not Applicable Not Applicable
South Korea Limited to the months of March–December in rural areas in the northern parts of Incheon, Kangwon-do, Kyônggi-do Provinces including the demilitarized zone (DMZ). None P. vivax 100% Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,5 or tafenoquine5

 
Provinces(s) of travel
Administrative divisions of South Korea
South Sudan, Republic of All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Spain None Not Applicable Not Applicable Not Applicable
Sri Lanka None Not applicable Not applicable Not applicable
Sudan All Chloroquine P. falciparum 90%;

P.vivax 5%–10%;

P. malariae and P. ovale rare.

 Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Suriname Present primarily in Sipaliwini Province by the border with French Guiana. Limited transmission also occurs in the provinces of Brokopondo, Marowijne, and Para by the border with French Guiana. No malaria in Paramaribo and provinces by the Atlantic Coast. Chloroquine P. falciparum 70%,

P. vivax 30%

 Sipaliwini Province by border with French Guiana: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5.
Other areas with malaria: None (mosquito avoidance only).6		 Province(s) of travel

Map provinces of Suriname to determine if a city is within a certain province
Sweden None Not Applicable Not Applicable Not Applicable
Switzerland None Not Applicable Not Applicable Not Applicable
Syria None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.